JNJ 54728518

Drug Profile

JNJ 54728518

Alternative Names: JNJ-54728518

Latest Information Update: 01 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Pharmaceuticals
  • Class Anorectics; Drug conjugates; Gastrointestinal hormones; Glucagon-like peptides; Obesity therapies; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon like peptide receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 07 Jul 2016 Phase-I clinical trials in Obesity in USA (unspecified route)
  • 07 Jul 2016 Phase-I clinical trials in Type-2 diabetes mellitus in USA (unspecified route)
  • 10 Jun 2016 Preclinical trials in Obesity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top